Consensus Report
Rapamycin
Moderate Consensus
out of 5
Based on 28 videos (38 hours analyzed) across 5 experts · Updated 2026-03-23
Expert Positions
The Verdict
Rapamycin is the most polarizing longevity intervention among the 5 experts. Attia is the most bullish, cautiously prescribing it to patients and calling it a potential 'gold standard' geroprotective molecule. Johnson experimented with it extensively but discontinued after experiencing side effects and finding a pre-print suggesting it accelerated biological aging. Huberman explicitly avoids it, citing insufficient human data. Hyman mentions it favorably as a cutting-edge longevity therapy but provides no direct protocol. Patrick discusses the mTOR pathway extensively but does not cover rapamycin as a supplement.
Where They Disagree
Attia cautiously prescribes rapamycin to patients and calls it a potential 'gold standard' geroprotective molecule, while Huberman explicitly avoids it and cites insufficient human evidence for longevity.
Johnson experimented with rapamycin extensively and concluded it accelerated his aging, while Attia continues to view it as one of the most promising longevity interventions when dosed correctly.
+ 3 more disagreements in the full report
About This Analysis
This consensus report on Rapamycin is based on 28 videos (38 hours analyzed) from five longevity experts: Andrew Huberman, Peter Attia, Rhonda Patrick, Bryan Johnson, and Mark Hyman. Each expert's position was independently analyzed from their published video content, including lectures, podcast episodes, and Q&A sessions with 1,000+ guest scientists.
The full report includes 8 key findings, dosage and protocol details, expert deep dives with direct video citations and timestamps, risk considerations, and related supplement synergies.
Unlock the Full Report
Get dosages, timing protocols, expert deep dives with video citations, and risks for Rapamycin.
Every recommendation traces back to a specific expert, video, and timestamp.
$9/month or $79/year · Cancel anytime